GlassScriptPhysician profile
Kent Kanatani
NPI 1649227471
$3,660.95
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $1,956 · 2021: $838.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $461.30 | 2019-2021 | |
| Lilly USA, LLC | $363.51 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $339.83 | 2019-2020 | |
| Abbvie INC. | $316.01 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $292.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $277.80 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $239.36 | 2019-2021 | |
| Novo Nordisk INC | $229.23 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.17 | 2019-2021 | |
| Glaxosmithkline, LLC. | $180.76 | 2019-2021 | |
| Allergan, INC. | $154.08 | 2019-2020 | |
| Ibsa Pharma INC. | $127.77 | 2019-2021 | |
| Abbott Laboratories | $103.42 | 2019-2021 | |
| Pfizer INC. | $70.07 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $65.28 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.59 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $37.99 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.05 | 2020 | |
| Xeris Pharmaceuticals, INC. | $32.88 | 2021 | |
| Daiichi Sankyo INC. | $24.29 | 2019 | |
| Shire North American Group INC | $21.50 | 2019 | |
| Astellas Pharma US INC | $13.98 | 2019 | |
| Eisai INC. | $13.84 | 2019 | |
| Mannkind Corporation | $11.79 | 2020 | |
| Amarin Pharma, INC. | $10.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Kanatani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.